Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: A lead-in study

Journal of Thoracic Oncology

Volumn 7, Issue 9, 2012, Pages 1406-1416

  Blumenschein, George R ^a   Ciuleanu, Tudor ^b   Robert, Francisco ^c   Groen, Harry J M ^d   Usari, Tiziana ^e   Ruiz Garcia, Ana ^f   Tye, Lesley ^f   Chao, Richard C ^g   Juhasz, Erzsebet ^h,i  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^c Central European Cooperative Oncology Group Austria   (Austria)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f PFIZER INC   (United States)

^g TORONTO GENERAL HOSPITAL   (Canada)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

Author keywords

Erlotinib; Non small cell lung cancer; Pharmacokinetics; Safety; Sunitinib

Indexed keywords

ERLOTINIB; N DEETHYLSUNITINIB; PLACEBO; SUNITINIB;

ABDOMINAL PAIN; ACNE; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; HEMOPTYSIS; HEMORRHOID; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; INFECTION; LEUKOCYTE COUNT; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MOUTH PAIN; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN TOXICITY; SORE THROAT; THORAX PAIN; THROMBOCYTOPENIA; UPPER ABDOMINAL PAIN;

EID: 84865690782     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31825cca1c     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Gabrielson E. Worldwide trends in lung cancer pathology. Respirology 2006;11:533-538. (Pubitemid 44186257)
3. Ginsberg MS, Grewal RK, Heelan RT. Lung cancer. Radiol Clin North Am 2007;45:21-43. (Pubitemid 44854042)
4. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-594. (Pubitemid 351720831)
5. Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001;19:1734-1742. (Pubitemid 32230875)
6. Schiller JH, Harrington D, Belani CP, et al.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98. (Pubitemid 34438899)
7. Ramalingam S Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008;13 Suppl 1:5-13.
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132. (Pubitemid 41058344)
9. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-478.
10. Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006;91:4070-4076. (Pubitemid 44536887)
11. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337. (Pubitemid 36109749)
12. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-3605. (Pubitemid 36857948)
13. Tibes R, Trent J, Kurzrock R. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu Rev Pharmacol Toxicol 2005;45:357-384. (Pubitemid 40261810)
14. Pfizer Inc. SUTENT® summary of product characteristics [electronic Medicines Compendium (eMC) website]. . Available at: http://www. medicines.org.uk/EMC/medicine/18531/SPC/SUTENT±12.5mg%2c± 25mg%2c±37.5mg±and±50mg±Hard±Capsules/. Accessed February 4, 2011.
15. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-513.
16. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26:650-656. (Pubitemid 351264362)
17. Novello S, Scagliotti GV, Rosell R, et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009;101:1543-1548.
18. Döme B, Hendrix MJ, Paku S, Tóvári J, Tímár J. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol 2007;170:1-15. (Pubitemid 47339184)
19. Tallquist M Kazlauskas A. PDGF signaling in cells and mice. Cytokine Growth Factor Rev 2004;15:205-213. (Pubitemid 38781046)
20. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676. (Pubitemid 36749215)
21. De Luca A, Carotenuto A, Rachiglio A, et al. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 2008;214:559-567. (Pubitemid 351224199)
22. Pietras K, Sjöblom T, Rubin K, Heldin CH, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 2003;3:439-443. (Pubitemid 38340290)
23. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
24. Hamilton M, Wolf JL, Rusk J, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006;12(7 Pt 1):2166-2171.
25. Ruinemans GM, Balemans C, Mattijssen V, Wiersma-van Tilburg AJ, Smit HJ. Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib. Lung Cancer 2010;70:364-365.
26. Chow LQ, Blais N, Jonker DJ, et al. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded
27. cohort in non-small cell lung cancer. Cancer Chemother Pharmacol 2012;69:709-722.
28. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009;14:253-263.
29. Cappuzzo F, Ciuleanu T, Stelmakh L, et al.; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-529.
30. O'Mahar SE, Campbell TC, Hoang T, et al. Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2011;6:951-953.
31. OSI Pharmaceuticals IGI TARCEVA® (erlotinib) prescribing information [Genentech website]. Available at: http://www.gene.com/gene/products/ information/pdf/tarceva-prescribing.pdf. Accessed February 4, 2011.
32. Pfizer Inc. SUTENT® (sunitinib) prescribing information [Pfizer website]. Available at: http://www.pfizer.com/files/products/uspi-sutent.pdf. Accessed February 4, 2011.
33. Li J, Zhao M, He P, Hidalgo M, Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007;13:3731-3737. (Pubitemid 46955138)
34. Groen HJ, Socinski MA, Grossi F, et al. Randomized phase II study of sunitinib (SU) plus erlotinib (E) vs. placebo (P) plus E for the treatment of metastatic non-small cell lung cancer (NSCLC). Ann Oncol 2010;21:Abstract 417P.
35. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/ pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010;66:357-371.